Trials / Conditions / Gastroenteropancreatic Neuroendocrine Tumor

Gastroenteropancreatic Neuroendocrine Tumor

22 registered clinical trials studyying Gastroenteropancreatic Neuroendocrine Tumor — 10 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs. NCT07165132	RayzeBio, Inc.	Phase 1
Recruiting	IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Asse NCT06790706	Hospices Civils de Lyon	Phase 2
Recruiting	Nutritional Status Assessment in Adult Patients Followed for Gastroenteropancreatic Neuroendocrine Tumors at S NCT07302100	University Hospital, Strasbourg, France	—
Terminated	Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Ne NCT05987176	Imperial College London	Phase 2
Recruiting	Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors NCT04090034	Methodist Health System	—
Recruiting	Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted NCT06256705	Assistance Publique - Hôpitaux de Paris	N/A
Recruiting	Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumo NCT05636618	Perspective Therapeutics	Phase 1 / Phase 2
Recruiting	Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients NCT05701241	University Hospital, Antwerp	Phase 4
Withdrawn	177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs NCT04915144	British Columbia Cancer Agency	Phase 2
Active Not Recruiting	NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Car NCT05262556	Amr Mohamed MD	Phase 1
Active Not Recruiting	Neuroendocrine Tumors - Patient Reported Outcomes NCT05064150	University of Iowa	—
Recruiting	Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Fo NCT05477576	RayzeBio, Inc.	Phase 3
Completed	Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs NCT04852679	Ipsen	Phase 3
Recruiting	Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Cand NCT04609592	Stanford University	Phase 1
Active Not Recruiting	Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Tre NCT04727723	Novartis Pharmaceuticals	—
Completed	Nutrition in Gastroenteropancreatic Neuroendocrine Tumor NCT04986085	Grupo Espanol de Tumores Neuroendocrinos	—
Completed	Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) NCT03980925	Grupo Espanol de Tumores Neuroendocrinos	Phase 2
Recruiting	68Ga-DOTATOC PET for the Evaluation of Gastroenteropancreatic Neuroendocrine Tumours NCT06155318	IRCCS San Raffaele	—
Completed	Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroend NCT03017690	Ipsen	—
Completed	Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors NCT02948946	H. Lee Moffitt Cancer Center and Research Institute	—
Completed	Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors NCT02611024	PharmaMar	Phase 1 / Phase 2
Terminated	A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor NCT01994213	Jiangsu HengRui Medicine Co., Ltd.	Phase 2